Sleep qual

Sleep quality and regular physical activity in reducing cardiac risk

BACKGROUND Adolescents with sedentary behavior, spending many hours in front of the television and electronic devices, develop early involvement of cardiovascular disease and obesity. These sedentary behaviors increased significantly in this age group during the pandemic of 2020/2021. Sleep directly influences aspects of health, such as blood pressure and cardiac autonomic balance and exercise has a protective effect on these same physiological parameters. OBJECTIVE This study aimed to examine whether or not physically active adolescents positively influence HRV and cardiovascular parameter...

CHEST Updates Practice Guideline on Perioperative Management of Antithrombotic Therapy

The American College of Chest Physicians (CHEST) published a new clinical guideline on the periopera...

Hypertension Increases Risk of Severe COVID-19, Even After Vaccination and Booster

Hypertension more than doubles the risk of hospitalisation related to infection with the Omicron var...


Suggested videos

Search:
Date
Filters:
Anticoagul
8:47

Anticoagulant Advancements for VTE in Children

Presenter: Heleen van Ommen
Internal Medicine
ISTH 2022
The Journe
3:15

The Journey to Address Unmet Needs Across all Haemophilia Indications

Presenter: Maria Elisa Mancuso
Internal Medicine
ISTH 2022
Good pract
19:37

Good practice statements for antithrombotic therapy in the management of COVID-19

Presenter: Alex Spyropoulos
Internal Medicine
ISTH 2022
Clinical C
6:18

Clinical Challenges in Patients with Venous Thromboembolism

Presenter: Walter Ageno
Internal Medicine
ISTH 2022
Navigating
4:20

Navigating the Joint Health Journey for Patients With Hemophilia: How Can You Make A Lasting Impact?

Presenter: Margareth C. Ozelo
Internal Medicine
ISTH 2022
ISTH Propo...
3:57

ISTH Proposal to Standardize Functional Assays in the Diagnosis of Heparin‐induced Thrombocytopenia

Presenter: Ishac Nazy
Internal Medicine
ISTH 2022
Approaches
4:22

Approaches to Standardisation and Monitoring for Haemophilia Gene Therapy: Consistency, Considerations and Challenges

Presenter: Johnny Mahlangu
Internal Medicine
ISTH 2022
Strategies
10:56

Strategies for Assessing and Managing DOAC-Related Bleeding

Presenter: Deborah Siegal
Internal Medicine
ISTH 2022
Diagnosis
9:40

Diagnosis and management of primary aldosteronism

Presenter: Paolo Mulatero
Cardiology : Hypertension
ESH 2022
Roles of F
5:02

Roles of FVIII in Endothelial Cell Biology: More than a Coagulation Factor?

Presenter: Antonia Follenzi
Internal Medicine
ISTH 2022
Comparison
5:05

Comparison between full dose and reduced dose enoxaparin in the management of cancer-associated venous thromboembolism

Presenter: Emma Leitinger
Internal Medicine
ISTH 2022
Special fo
13:43

Special forms of hypertension, optomized prevention and hypertension epidemiology: Novelties from ESH 2022

Presenter: Gianfranco Parati
Cardiology : Hypertension
ESH 2022
Brain canc
5:56

Brain cancers and the risk of intracranial hemorrhage with Direct Oral Anticoagulants versus Low Molecular Weight Heparin

Presenter: Philip Haddad
Internal Medicine
ISTH 2022
Adherence
11:40

Adherence to antihypertensive treatment in patients with CKD: a barrier to optimal renoprotection

Presenter: Michel Burnier
Cardiology : Hypertension
ESH 2022
The SAXOPH
6:02

The SAXOPHONE Study

Presenter: Mark R. Payne
Internal Medicine
ISTH 2022
ISTH Guide
10:60

ISTH Guidelines for Anticoagulation in COVID-19

Presenter: Sam Schulman
Internal Medicine
ISTH 2022
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
Long-term
8:46

Long-term efficacy and safety of ixekizumab

Presenter: Andrew Blauvelt
Dermatology
Paradigm s
12:05

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Presenter: Federico Cappuzzo
Oncology
How will t
9:43

How will the current therapeutic options change the treatment of RCC in the daily practice?

Presenter: Camillo Porta
Oncology
The role o
5:58

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Presenter: David F. McDermott
Oncology
Treatment
11:50

Treatment intensification in the treatment of prostate cancer

Presenter: Oliver Sartor
Oncology
Pembrolizu
16:35

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Presenter: Stefan N. Symeonides
Oncology
State of t
6:13

State of the art treatment of bladder cancer

Presenter: Matthew R. Zibelman
Oncology
First-line
7:41

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer

Presenter: Ken Kato
Oncology
Treatment
3:27

Treatment of iron deficiency in acute and chronic heart failure

Presenter: Piotr Ponikowski
Cardiology
Alcohol se
6:32

Alcohol septal ablation in hypertrophic cardiomyopathy: past and future

Presenter: Hubert Seggewiss
Cardiology
The use of
3:35

The use of SGLT2 inhibitors in the prevention and treatment of heart failure

Presenter: Petar M. Seferovic
Cardiology
Direct myo
5:15

Direct myosin inhibitors in hypertrophic cardiomyopathy: a new era?

Presenter: Iacopo Olivotto
Cardiology
Diagnostic
10:55

Diagnostic delay in pulmonary arterial hypertension

Presenter: Barbro Kjellström and Bodil Ivarsson
Clinical I
6:21

Clinical Impact of Liraglutide as a Treatment of Obesity

Presenter: Babak Dehestani
Internal Medicine
Associatio
20:17

Association of GLP 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events

Presenter: Michael Camilleri
Internal Medicine
Liraglutid
13:26

Liraglutide for Weight Management in the Real World

Presenter: Roman Vangoitsenhoven
Cardiology , Diabetology